Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

In pharmacovigilance, effective search strings are key

Posted on February 9th, 2018 by in Pharmacovigilance

A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. Continue reading “In pharmacovigilance, effective search strings are key” »

Why a reliable FAERS searching capability is essential for pharma companies

Posted on October 27th, 2017 by in Pharmacovigilance

In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »

The Liabilities of Pharmacovigilance Activities

Posted on June 21st, 2017 by in Pharmacovigilance

There is always a risk that any Pharmacovigilance (PV) activity, even executed with the highest business and ethical standards, and with the highest compliance results, could be challenged, sometimes many years later. As a member of a PV team, you may have to one day justify your actions in front of a group of plaintiff’s lawyers, Continue reading “The Liabilities of Pharmacovigilance Activities” »

What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?

Posted on June 14th, 2017 by in Pharmacovigilance

The health and safety of patients is of utmost concern to pharmaceutical companies, and strict regulatory requirements ensure that safety standards remain high. But pharmacovigilance becomes an ever more difficult and overwhelming practice Continue reading “What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?” »

  1. 1
  2. 2
  3. 3
  4. 5